Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 85, Issue 3 PART A, 2013, Pages 463-472

  Mattu, C ^a   Pabari, R M ^b   Boffito, M ^a   Sartori, S ^a   Ciardelli, G ^a,c   Ramtoola, Z ^b  

^a POLITECNICO DI TORINO   (Italy)

^b Royal College of Ireland   (Ireland)

^c CNR   (Italy)

Author keywords

Cancer targeting; Herceptin; Nanoparticles; Paclitaxel; Polyesterurethanes

Indexed keywords

COUMARIN DERIVATIVE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIDE; POLYURETHAN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CELL; CELL STRAIN MCF 7; CONFOCAL MICROSCOPY; DRUG ABSORPTION; DRUG ADSORPTION; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RELEASE; DRUG TARGETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; IC 50; IN VITRO STUDY; INFRARED SPECTROSCOPY; INTERNALIZATION; OVARY CANCER; STATIC ELECTRICITY; TUMOR CELL LINE; ZETA POTENTIAL;

CANCER TARGETING; HERCEPTIN; NANOPARTICLES; PACLITAXEL; POLYESTERURETHANES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MCF-7 CELLS; NANOPARTICLES; PACLITAXEL; POLYMERS;

EID: 84888372831     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.07.016     Document Type: Article

References (28)

1. B. Haley, and E. Frenkel Nanoparticles for drug delivery in cancer treatment Urol. Oncol. 26 2008 57 64
2. A. Kumari, S.K. Yadav, and S.C. Yadav Biodegradable polymeric nanoparticles based drug delivery systems Colloids Surf. B 75 2010 1 18
3. M.L. Hans, and A.M. Lowman Biodegradable nanoparticles for drug delivery and targeting Curr. Opin. Solid State Mater. Sci. 6 2002 319 327
4. S. Parveen, R. Misra, and S.K. Sahoo Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging Nanomed. Nanotechnol. Biol. Med. 8 2012 147 166
5. W.P. McGuire 3rd, and M. Markman Primary ovarian cancer chemotherapy: current standards of care Br. J. Cancer 89 2003 S3 8
6. S. Parveen, and S.K. Sahoo Polymeric nanoparticles for cancer therapy J. Drug Target. 16 2008 108 123
7. S. Acharya, F. Dilnawaz, and S.K. Sahoo Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy Biomaterials 30 2009 5737 5750
8. M.C. Garnett Targeted drug conjugates: principles and progress Adv. Drug Del. Rev. 53 2001 171 216
9. J.M. Lambert Drug-conjugated monoclonal antibodies for the treatment of cancer Curr. Opin. Pharmacol. 5 2005 543 549
10. A. Funaro, A.L. Horenstein, P. Santoro, C. Cinti, A. Gregorini, and F. Malavasi Monoclonal antibodies and therapy of human cancers Biotechnol. Adv. 18 2000 385 401
11. G. Köhler, and C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495 497
12. Patrick Vermette, Hans J. Griesser, GaZtan Laroche, G. Robert, Tissue Engineering Intelligence Unit 6: Biomedical Application of Polyurethanes, Landes Bioscience, Texas (USA), 2001.
13. C. Mattu, M. Boffito, S. Sartori, E. Ranzato, E. Bernardi, M.P. Sassi, A.M. Di Rienzo, and G. Ciardelli Therapeutic nanoparticles from novel multiblock engineered polyesterurethanes J. Nanopart. Res. 14 2012 1306
14. P. Kocbek, N. Obermajer, M. Cegnar, J. Kos, and J. Kristl Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody J. Controlled Release 120 2007 18 26
15. A. Cirstoiu-Hapca, F. Buchegger, N. Lange, L. Bossy, R. Gurny, and F. Delie Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice J. Controlled Release 144 2010 324 331
16. R.M. Pabari, B. Ryan, C. McCarthy, and Z. Ramtoola Effect of microencapsulation shear stress on the structural integrity and biological activity of a model monoclonal antibody, trastuzumab Pharmaceutics 3 2011 510 524
17. Y. Liu, K. Li, B. Liu, and S.S. Feng A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery Biomaterials 31 2010 9145 9155
18. G. Arya, M. Vandana, S. Acharya, and S.K. Sahoo Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy Nanomedicine 7 2011 859 870
19. P. Birner, G. Oberhuber, J. Stani, C. Reithofer, H. Samonigg, H. Hausmaninger, E. Kubista, W. Kwasny, D. Kandioler-Eckersberger, M. Gnant, and R. Jakesz The Austrian breast and colorectal cancer study group, evaluation of the United States food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer Clin. Cancer Res. 7 2001 1669 1675
20. P. Cerrai, G.D. Guerra, L. Lelli, M. Tricoli, R. Sbarbati Del Guerra, M.G. Cascone, and P. Giusti Poly(ester-ether-ester) block copolymers as biomaterial J. Mater. Sci. Mater. Med. 5 1994 33 39
21. A. Rechichi, G. Ciardelli, M. D'Acunto, G. Vozzi, and P. Giusti Degradable block polyurethanes from nontoxic building blocks as scaffold materials to support cell growth and proliferation J. Biomed. Mater. Res. A 84 2008 847 855
22. Z. Ramtoola, P. Lyons, K. Keohane, S.W. Kerrigan, B.P. Kirby, and J.G. Kelly Investigation of the interaction of biodegradable micro- and nanoparticulate drug delivery systems with platelets J. Pharm. Pharmacol. 63 2011 26 32
23. B. Sun, B. Ranganathan, and S.-S. Feng Multifunctional poly(d,l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer Biomaterials 29 2008 475 486
24. K. Mukherjee, V. Syed, and S.M. Ho Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells Oncogene 24 2005 4388 4400
25. C. Cai, U. Bakowsky, E. Rytting, A.K. Schaper, and T. Kissel Charged nanoparticles as protein delivery systems: a feasibility study using lysozyme as model protein Eur. J. Pharm. Biopharm. 69 2008 31 42
26. I. Steinhauser, B. Spänkuch, K. Strebhardt, and K. Langer Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells Biomaterials 27 2006 4975 4983
27. Z. Wei, J. Feng, H.Y. Lin, S. Mullapudi, E. Bishop, G.I. Tous, J. Casas-Finet, F. Hakki, R. Strouse, and M.A. Schenerman Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus Anal. Chem. 79 2007 2797 2805
28. N.M.K. Lamda, K.A. Woodhouse, and S.L. Cooper Polyurethanes in Biomedical Applications 1998 CRC Press USA